StrataMGT is a suitable alternative treatment for women suffering from various highly symptomatic vulvovaginal conditions.
A 52-women open-label, single-arm intervention study was conducted in St. Andrews War Memorial Hospital in Brisbane,
Australia to evaluate the efficacy and safety of StrataMGT for the management of genital skin conditions.
Patients were diagnosed with Genitourinary Syndrome of Menopause (GSM), Lichen Sclerosus (LS) and Lichen Simplex
Chronicus (LSC), and applied the product daily internally and externally to the genital area for approximately 6 months
(short-term analysis, n=52) and up to 2 years (long-term analysis, n=30).
Data on file, 2022. (St. Andrews War Memorial Hospital, Australia). Stratpharma AG.
Severity of the symptoms: Patients rated severity of the symptoms using a 10-point scale ranging from 0=normal to 10=worst possible.
• The most significant improvements were seen during the first 6 weeks, where symptoms improved up to a 100% resolution for some patients. Favorable results were maintained after 2 years post start of the treatment.
• StrataMGT reduces Trans-Epidermal Water Loss (TEWL) by preventing water loss from
epidermal and dermal layers, and gas permeability enables a better environment for
epidermal migration and healing.
• Patient compliance was very high throughout the study, between 86% and 97% in each
visit interval. No adverse events were observed.
A 52-women open-label, single-arm intervention study was conducted in St. Andrews War Memorial Hospital in Brisbane,
Australia to evaluate the efficacy and safety of StrataMGT for the management of genital skin conditions.
Patients were diagnosed with Genitourinary Syndrome of Menopause (GSM), Lichen Sclerosus (LS) and Lichen Simplex
Chronicus (LSC), and applied the product daily internally and externally to the genital area for approximately 6 months
(short-term analysis, n=52) and up to 2 years (long-term analysis, n=30).
Data on file, 2022. (St. Andrews War Memorial Hospital, Australia). Stratpharma AG.
Severity of the symptoms: Patients rated severity of the symptoms using a 10-point scale ranging from 0=normal to 10=worst possible.
• The most significant improvements were seen during the first 6 weeks, where symptoms improved up to a 100% resolution for some patients. Favorable results were maintained after 2 years post start of the treatment.
• StrataMGT reduces Trans-Epidermal Water Loss (TEWL) by preventing water loss from
epidermal and dermal layers, and gas permeability enables a better environment for
epidermal migration and healing.
• Patient compliance was very high throughout the study, between 86% and 97% in each
visit interval. No adverse events were observed.
A 9-women non-randomized, open-label intervention study was conducted in Orange Coast Women‘s Medical Group in Laguna Hills, California, USA to evaluate the efficacy and safety of StrataMGT and the improvement of patient‘s Quality-of-Life (QoL). All patients were postmenopausal, diagnosed with GSM, and treated with StrataMGT for 2 months.
Patients rated the impact of vulvar conditions on QoL using Vulvar Quality of Life Index (VQLI) ranging from 0=not impacted, 1-15=mildly impacted, 16-30=moderately impacted, 31-45=severely impacted.
Data on file, 2022. (St. Andrews War Memorial Hospital, Australia). Stratpharma AG.
• The most significant improvement was seen during the first month of treatment - the VQLI score reduced by 54%.
• StrataMGT is highly efficient in reducing clinical symptoms
associated with GSM and significant improvement of QoL.
